Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol (Diabetes Therapy, (2018), 9, 1, (37-47), 10.1007/s13300-017-0330-z)

Abstract

In the original publication, the text in Table 2 stated ‘Hypersensitivity to the active substance, to Ferinject, or to any of its excipients’. The authors would like to make changes to the text and have replaced it to ‘Hypersensitivity to ferric carboxymaltose or to any of the excipients of the study medication’. The authors have also made alterations to Fig. 1. Corrected Fig. 1 and Table 2 are given below: (Figure presented.).